Tyr905
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr905  -  Ret (human)

Site Information
DVyEEDsyVKRsQGR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447627
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 39 ) , immunoprecipitation ( 3 , 39 ) , mass spectrometry ( 4 , 5 , 7 , 8 , 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 27 , 28 , 30 , 31 , 32 , 33 ) , mass spectrometry (in vitro) ( 25 ) , microscopy-colocalization with upstream kinase ( 35 ) , mutation of modification site ( 34 , 35 , 36 , 37 , 38 , 39 ) , phospho-antibody ( 2 , 3 , 6 , 11 , 21 , 26 , 29 , 35 , 36 , 37 , 38 ) , phosphoamino acid analysis ( 39 ) , western blotting ( 2 , 3 , 6 , 11 , 21 , 26 , 29 , 35 , 36 , 37 , 38 , 39 )
Disease tissue studied:
adrenal cancer ( 35 ) , pheochromocytoma ( 35 ) , bone cancer ( 5 ) , Ewing's sarcoma ( 5 ) , brain cancer ( 31 , 32 ) , breast cancer ( 28 ) , leukemia ( 30 ) , acute myelogenous leukemia ( 8 , 30 ) , lung cancer ( 33 ) , small-cell lung cancer ( 33 ) , neuroblastoma ( 4 , 9 , 10 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 24 , 27 , 31 , 32 , 37 ) , ovarian cancer ( 12 , 22 ) , thyroid cancer ( 29 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
Ret (human) ( 6 , 26 , 35 )
Putative in vivo kinases:
FAK (human) ( 6 ) , Src (mouse) ( 36 )
Kinases, in vitro:
FAK (human) ( 6 ) , Ret (human) ( 34 , 37 ) , Src (human) ( 36 )
Putative upstream phosphatases:
PTPRJ (human) ( 29 )
Phosphatases, in vitro:
PTPRJ (human) ( 29 )
Treatments:
17-DMAG ( 2 ) , ART ( 37 ) , GDNF ( 21 , 37 ) , imatinib ( 6 ) , neurturin ( 37 ) , NVP-TAE226 ( 6 ) , orantinib ( 26 ) , PP1 ( 6 ) , semaxanib ( 26 ) , sorafenib ( 6 ) , sunitinib ( 26 )

Downstream Regulation
Effects of modification on Ret:
enzymatic activity, induced ( 1 , 25 , 34 , 36 , 37 , 39 ) , molecular association, regulation ( 3 ) , phosphorylation ( 38 )
Effects of modification on biological processes:
cell growth, altered ( 34 , 35 , 36 , 38 , 39 )
Induce interaction with:
VAV1 (mouse) ( 3 )

References 

1

Plaza-Menacho I, et al. (2016) RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements. Cell Rep 17, 3319-3332
28009299   Curated Info

2

Safavi S, et al. (2016) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget 7, 433-45
26595521   Curated Info

3

Zhu S, et al. (2015) Identification of a Vav2-dependent mechanism for GDNF/Ret control of mesolimbic DAT trafficking. Nat Neurosci 18, 1084-93
26147533   Curated Info

4

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

5

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

6

Plaza-Menacho I, et al. (2011) Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem 286, 17292-302
21454698   Curated Info

7

Ding VM, et al. (2011) Tyrosine phosphorylation profiling in fgf-2 stimulated human embryonic stem cells. PLoS One 6, e17538
21437283   Curated Info

8

Gu TL, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6, e19169
21552520   Curated Info

9

Guo A (2010) CST Curation Set: 10555; Year: 2010; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Guo A (2010) CST Curation Set: 10551; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Toledo RA, et al. (2010) High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. J Clin Endocrinol Metab 95, 1318-27
20080836   Curated Info

12

Ren H (2010) CST Curation Set: 8825; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Guo A (2009) CST Curation Set: 6124; Year: 2009; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Guo A (2009) CST Curation Set: 6121; Year: 2009; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Guo A (2009) CST Curation Set: 6123; Year: 2009; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Guo A (2009) CST Curation Set: 6122; Year: 2009; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Stokes M (2008) CST Curation Set: 5269; Year: 2008; Biosample/Treatment: cell line, LAN-6/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Stokes M (2008) CST Curation Set: 5270; Year: 2008; Biosample/Treatment: cell line, LAN-6/untreated; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Stokes M (2008) CST Curation Set: 5271; Year: 2008; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Stokes M (2008) CST Curation Set: 5272; Year: 2008; Biosample/Treatment: cell line, LAN-6/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

21

Runeberg-Roos P, Virtanen H, Saarma M (2007) RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface. Oncogene 26, 7909-15
17599050   Curated Info

22

Ren H (2007) CST Curation Set: 3470; Year: 2007; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Cherry J (2007) CST Curation Set: 2527; Year: 2007; Biosample/Treatment: cell line, Nomo-1/SAHA 6h; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Stokes M (2006) CST Curation Set: 2043; Year: 2006; Biosample/Treatment: cell line, LAN-1/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

25

Knowles PP, et al. (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281, 33577-87
16928683   Curated Info

26

Kim DW, et al. (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91, 4070-6
16849418   Curated Info

27

Stokes M (2006) CST Curation Set: 1764; Year: 2006; Biosample/Treatment: cell line, SKNFI/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Michaud C (2006) CST Curation Set: 1701; Year: 2006; Biosample/Treatment: cell line, EVSA-T/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Iervolino A, et al. (2006) The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins. Cancer Res 66, 6280-7
16778204   Curated Info

30

Gu T (2006) CST Curation Set: 1413; Year: 2006; Biosample/Treatment: cell line, MV4-11/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Stokes M (2006) CST Curation Set: 1206; Year: 2006; Biosample/Treatment: cell line, CHP212/serum starved; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Stokes M (2006) CST Curation Set: 1121; Year: 2006; Biosample/Treatment: cell line, SKNAS/serum starved; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

33

Farnsworth C (2005) CST Curation Set: 735; Year: 2005; Biosample/Treatment: cell line, DMS53/serum starved; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Kawamoto Y, et al. (2004) Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem 279, 14213-24
14711813   Curated Info

35

Buckwalter TL, et al. (2002) The roles of phosphotyrosines-294, -404, and -451 in RET/PTC1-induced thyroid tumor formation. Oncogene 21, 8166-72
12444552   Curated Info

36

Kato M, et al. (2002) Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine. Cancer Res 62, 2414-22
11956105   Curated Info

37

Coulpier M, Anders J, Ibáñez CF (2002) Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. J Biol Chem 277, 1991-9
11713247   Curated Info

38

Iwashita T, et al. (1999) Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18, 3919-22
10445857   Curated Info

39

Iwashita T, et al. (1996) Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene 12, 481-7
8637703   Curated Info